[{"id":"164de5d7-d0fe-446f-8ed5-922f4ae51531","acronym":"","url":"https://clinicaltrials.gov/study/NCT02544633","created_at":"2021-01-18T12:18:40.409Z","updated_at":"2024-07-02T16:36:49.218Z","phase":"Phase 2","brief_title":"Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET","source_id_and_acronym":"NCT02544633","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glesatinib (MGCD265)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 04/30/2018","primary_completion_date":" 04/30/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2020-03-04"},{"id":"0550fb9c-b9bd-4921-9d69-c2e4ef4dcbf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00697632","created_at":"2021-01-18T02:36:31.892Z","updated_at":"2024-07-02T16:37:02.876Z","phase":"Phase 1","brief_title":"Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies","source_id_and_acronym":"NCT00697632","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MET • AXL","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • AXL expression","tags":["MET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • AXL expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glesatinib (MGCD265)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-12"}]